论文部分内容阅读
目的:采用Meta分析方法评价生脉注射液治疗缺血性中风的有效性和安全性.方法:计算机检索PubMed、Medline、Embase、the Cochrane Library、中国知网(CNKI)、万方数据库、维普数据库(VIP)等电子数据库中应用生脉注射液治疗缺血性中风患者的随机对照试验(RCTs).使用Cochrane协作网工具评价纳入文献的方法学质量,采用RevMan 5.3.3软件进行Meta分析.结果:共纳入8个RCT,累计745例缺血性中风患者,纳入的8篇文献均为中低质量研究.Meta分析结果显示,在缺血性中风的常规治疗基础上,联用生脉注射液可明显提高总有效率(RR=1.24,95％ CI:1.15～1.33,P＜0.000 01,nRCT=7)、降低神经功能缺损程度评分(MD=-4.51,95％ CI:-6.02 ～-3.00,P＜0.000 01,nRcT =5)及提高日常生活活动能力评分(nRCT=2).结论:常规治疗基础上联用生脉注射液治疗缺血性中风具有一定的疗效,且不增加不良反应.但由于本Meta分析纳入研究质量不高,有必要开展更多设计严谨、大样本、多中心RCT加以验证.“,”Objective:To review the effectiveness and saftey of Shengmai injection in treatment for ischemic stroke.Methods:Databases of PubMed,Medline,Embase,the Cochrane Library,CNKI,Wanfang data and VIP were retrieved for collecting the randomized controlled trials (RCTs) of the treatment for ischemic stroke with Shengmai injection.Based on strict quality evaluation,RevMan 5.3.3 software was use to conduct Mate-analysis along with the application of Cochrane Collaboration tools appraise the methodological quality of included studies.Results:An amount of 8 RCTs involving 745 patients was included in the thesis,of which all the included cases were low-quality studies.Based on the Metaanalysis conducted,an result of total effective rate (RR =1.24,95％ CI:1.15-1.33,P ＜ 0.000 01,nRtcT =7),neurological deficit score (MD =-4.51,95％ CI:-6.02--3.00,P ＜ 0.000 01,n RcT =5) and activities of daily living score of showed that Shengmai injection treatment was superior to the conventional routine treatment (nRCT =2).Conclusion:Routine treatment combined Shengmai injection had shown better curative effect on ischemic stroke and less adverse reactions.Given that the only several low-quality cases were included in this Meta-analysis,more RCTs with rigorous design,large scale and multi-center were needed for further corroboration of this tendency.